1. Analyst View
2. The Global Vaccine Market
2.1 Introduction
2.2 Market Opportunity Assessment
3. Critical Success and Risk Factors
3.1 Critical Success Factors
3.1.1 Disease Prevention
3.1.2 Higher Margins
3.1.3 Support from Government and NGOs
3.1.4 Blockbuster Potential of New Vaccines
3.2 Critical Risk Factors
3.2.1 Huge R&D Cost
3.2.2 Immunization Safety
3.2.3 Inequality in Distribution
3.2.4 Lack of Infrastructure for Trials and Manufacturing
3.2.5 Effective Vaccine Design
3.2.6 Vaccine Supply
4. Major Vaccine Segments
4.1 Basic Pediatrics
4.2 Enhanced Pediatrics
4.3 Proprietary Pediatrics
4.4 Adult Vaccines
4.4.1 Cancer Vaccines
4.4.2 Addiction Vaccines
4.4.3 Influenza Vaccines
5. Major Pediatric Vaccines
5.1 Pneumococcal Vaccines
5.2 Polio Vaccines
5.3 Varicella Vaccines
5.4 Meningitis Vaccines
5.5 Rotavirus Vaccines
5.6 DTP Vaccines
5.7 Measles, Mumps & Rubella (MMR) Vaccines
5.8 Tuberculosis Vaccines
6. Major Adult/Travel & Therapeutic Vaccines
6.1 Hepatitis B Vaccines
6.2 Malaria Vaccines
6.3 Japanese Encephalitis Vaccines
6.4 Ebola Vaccines
6.5 Cervical Cancer Vaccines
6.6 Typhoid Vaccines
6.7 West Nile Vaccines
6.8 HIV Vaccines
7. Key Geographical Markets
7.1 US
7.2 Europe
7.3 China
7.4 India
7.5 Japan
7.6 Brazil
8. Competitive Landscape to 2012
8.1 Revenues and Growth of Key Players
8.2 Revenues and Growth of Key Vaccine Brands
8.3 Key Mergers and Acquisitions
8.4 Major Categories of Players
8.4.1 Vaccine Majors
8.4.2 Vaccine-focused Biotech Companies
8.4.3 Domestic-focused Vaccine Companies
8.5 Key Company Profiles
8.5.1 Sanofi-Aventis
8.5.2 GlaxoSmithKline Plc.
8.5.3 Merck & Co., Inc.
8.5.4 Novartis
8.5.5 Wyeth
